Cardiovascular and metabolic diseases including obesity remain important areas of unmet medical need, and we plan to continue applying our global capabilities to advance a pipeline of investigational treatments that have the potential to fill critical gaps in patient care, including continued development of our oral GIPR antagonist candidate and other earlier obesity programs, said Chris Boshoff, MD, PhD, Chief Scientific Officer and President, Research and Development at Pfizer
Understanding this distinction is the absolute foundation of proper handling
PlexusDx ensures all medications come from licensed 503A compounding pharmacies, maintaining pharmaceutical quality and purity that match or exceed FDA standards for brand-name products
Zepbound (tirzepatide) is another similar option to support weight loss in patients with obesity
No apto para embarazadas o personas en periodo de lactancia
10.1517/17425247.2012.666968 192 RajanalaS.MaymoneM